Tagged with access,

association The industry of medical devices is still not very well understood. Pablo Dávila shared with us his overview on the Mexican market, how the Mexican Association of Innovative Medical Device Industries (AMID) is interested on putting the sector on the map. Could you please tell us a bit more about…

MSD The managing director of MSD in Mexico explains why the Mexican pharmaceutical market is an attractive market in which to compete, but not one that will deliver 12 to 15 percent growth year on year, why 2014 has been a tough year for the sector and how MSD is focusing…

Janssen The country manager of one of the foremost providers of sustainable and integrated healthcare solutions describes the sorts of local adaptations that need to be enacted when launching a product on the Romanian market. He also speaks extensively about the state of the local medical device market and its likely future potential. Can…

Lilly A recent arrival from China, Lilly’s Turkey MD Daniel Lucas assesses the country’s healthcare system and raises key questions about the sustainability of the system at large going forward, and the authorities’ approach to reform. You came to Turkey in October after more than four years in China. What is your…

MSD MSD Turkey has benefited in recent years from the ability to engage in local business development initiatives, and managing director Hatice Demiray has prioritized initiatives such as reducing internal bureaucracy and incentivizing CRM use to improve operational efficiencies. You took over last year as managing director of MSD Turkey, after…

GSK GSK’s VP and Area GM Pharmaceuticals, Turkey and Caucasus, and chairman of Turkey’s innovative pharmaceutical association, discusses the effectiveness of the government’s current strategy for reducing the trade deficit in the pharmaceutical industry, and the need for the industry and government to approach all discussions with a partnership mentality. Do…

Biocodex Biocodex’s new general manager gives an overview of the affiliates ‘new deal’ program, and how the company has adjusted its approach to better fit the contemporary Turkish environment. What attracted you to Biocodex Turkey? What are your impressions of the business so far? Biocodex made the right decision in starting…

Daiichi Sankyo The general manager of Daiichi Sankyo Turkey discusses his affiliate’s expansion into a regional hub, current strategies for growth in the Turkish market, and the keys behind his affiliates multiple ‘great place to work’ awards.  In 2012, you had made it a goal to develop the Turkish affiliate into a regional…

Ferring The general manager of a speciality biopharma business challenges lawmakers to regard health spending not as a cost but as an investment and reveals how women’s healthcare and fertility treatment can become showcase examples in making Romanian healthcare sustainable. Back in 2011, when we asked you about Ferring’s priorities in…

Pfizer One of the new cohort of country managers speaks out about Romania’s blossoming potential as a manufacturing hub and explains in detail how his firm is diverting product lines form elsewhere in Europe and relocating them in Cluj so as to exploit what he sees as a real competitive advantage.…

Pfizer The country manager and Global Established Products Business Lead at Pfizer South Africa reveals how the private sector is committed to expanding healthcare for South Africans, why her ambition is to devise different sustainable business models that allow for more affordable medicines, and how Pfizer must crack the emerging market…

government In public health everything is a priority. The Undersecretary of Prevention and Health Promotion explains how Mexico’s Ministry of Health is handling the country’s changing epidemiological profile without forgetting communicable diseases and other urgencies affecting the Mexican population. You have been reappointed as Undersecretary of Prevention and Health Promotion in…